Kareus Therapeutics, SA - Product Pipeline Review - 2015
Global Markets Direct’s, ‘Kareus Therapeutics, SA - Product Pipeline Review - 2015’, provides an overview of the Kareus Therapeutics, SA’s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Kareus Therapeutics, SA’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- The report provides brief overview of Kareus Therapeutics, SA including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Kareus Therapeutics, SA’s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Kareus Therapeutics, SA’s pipeline products
Reasons to buy
- Evaluate Kareus Therapeutics, SA’s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Kareus Therapeutics, SA in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Kareus Therapeutics, SA’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Kareus Therapeutics, SA and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Kareus Therapeutics, SA - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Kareus Therapeutics, SA and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Our reports have been used by over 10K customers, including:
Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2018 Summary Toll Like Receptor 8 (CD288 or TLR8) - Toll-like receptor 8 is a protein encoded by the TLR8 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via...
The Global Antibiotics Partnering Terms and Agreements 2010 to 2018 report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in antibiotics partnering deals Disclosed headlines, upfronts, milestones and royalties...
110 pages •
By Infiniti Research Limited
• Nov 2018
About Peanut Allergy Peanut allergy is one of the most common types of food allergies that results in itchiness, abdominal pain, swelling, sneezing, diarrhea, and cardiac arrest. Technavio’s analysts forecast the Global Peanut Allergy Market to grow at a CAGR of 89.68% during the period 2019-2023. Covered...
113 pages •
By Infiniti Research Limited
• Oct 2018
About Antisense and RNAi Therapeutics Antisense and RNAi therapeutics are novel therapeutic options with potential to treat diseases such as chronic liver and cardiovascular diseases, Huntington disease, and even rare diseases. Technavio’s analysts forecast the Global Antisense and RNAi Therapeutics Market to grow...
Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2018 Summary Human Papillomavirus Protein E6 (E6) - The Human Papillomavirus (HPV) E6 protein is one of oncoproteins encoded by the virus. It is a 151 amino-acid peptide. It plays a major role in the induction and maintenance of cellular...
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 220.127.116.11 or EC 18.104.22.168) - Pipeline Review, H2 2018 Summary According to the recently published report ’Cytochrome P450 11B2 Mitochondrial - Pipeline...
Report Synopsis Personalized medicine has a huge potential in leading the healthcare industry with drastic changes with a key focus on diseases understanding & management integrated with advanced analytics, patient data, customized medicines and other possibilities. Personalized Medicine will transform the entire pharmaceutical...